Valuation: Genelux Corporation

Market Cap 130M 114M 105M 96.96M 183M 12.55B 186M 1.26B 494M 6.14B 489M 478M 21.15B P/E 2026 *
-3.57x
P/E 2027 * -3.92x
Enterprise Value 130M 114M 105M 96.96M 183M 12.55B 186M 1.26B 494M 6.14B 489M 478M 21.15B EV / Sales 2026 *
-
EV / Sales 2027 * 10.7x
Free-Float
86.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.09%
1 week-1.01%
Current month-2.66%
1 month-1.18%
3 months+10.57%
6 months+7.33%
Current year-32.80%
1 week 2.78
Extreme 2.775
2.97
1 month 2.78
Extreme 2.775
3.18
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 2014-05-27
Director of Finance/CFO 42 2025-01-29
Chief Tech/Sci/R&D Officer 52 2026-01-01
Director TitleAgeSince
Director/Board Member 68 2002-08-31
Chairman 73 2013-12-31
Chairman 67 2023-03-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Director

-12,000 0.0268%
6/16/26 Free

Chief Financial Officer

278,906 0.6220%
6/16/26 Free

Director

59,975 0.1338%
Change 5-day change 1-year change 3-year change Capi.($)
+2.09%-1.01%-12.01%-87.87% 130M
+0.35%-0.66%+56.56%+53.76% 53.79B
+5.37%+3.31%+50.39%+83.65% 54.69B
-1.20%-1.94%+4.35%+402.68% 23.2B
+0.74%+2.32%-16.23%-14.44% 23.31B
+1.46%+1.62%+38.64%-4.62% 20.03B
-0.43%-1.18%+32.09%-33.98% 17.31B
-1.67%-6.00%+163.95%+284.69% 14.99B
+1.49%+2.67%+35.46%+586.58% 15.36B
-0.70%-0.91%+24.87%+179.47% 13.96B
Average +0.75%-0.74%+37.81%+144.99% 23.68B
Weighted average by Cap. +1.32%-0.93%+43.08%+133.32%

Financials

2026 *2027 *
Net sales - 12.18M 10.68M 9.87M 9.08M 17.13M 1.17B 17.4M 118M 46.26M 575M 45.74M 44.75M 1.98B
Net income -37.1M -32.52M -30.06M -27.64M -52.16M -3.58B -53M -359M -141M -1.75B -139M -136M -6.03B -37.87M -33.19M -30.68M -28.22M -53.24M -3.65B -54.09M -367M -144M -1.79B -142M -139M -6.16B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
26-07-20 US$2.930 +2.09% 165,686
26-07-17 US$2.870 +1.77% 77,177
26-07-16 US$2.820 -3.09% 185,460
26-07-15 US$2.910 +0.69% 169,710
26-07-14 US$2.890 -2.36% 178,480
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.930USD
Average target price
17.50USD
Spread / Average Target
+497.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock